Minimising risk in first-in-man trials.
Hemelaar
Joris
J
Magdalen College, Oxford University, Oxford OX1 4AU, UK. Electronic address: joris.hemelaar@trinity.oxon.org.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D009102:Multiple Organ Failure / Q000139:chemically induced*; D016032:Randomized Controlled Trials as Topic / Q000009:adverse effects* / Q000379:methods; D018570:Risk Assessment
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C509303:TGN-1412